Viability of Plasmodium falciparum ex vivo: Comparison of the effects of artemether and sulfadoxine-pyrimethamine

European Journal of Clinical Pharmacology

Volumn 54, Issue 3, 1998, Pages 221-226

  Sowunmi, A ^a,b   Oduola, A M J ^a  

^a UNIVERSITY OF IBADAN   (Nigeria)

^b UNIVERSITY OF IBADAN   (Nigeria)

Author keywords

Artemether; Malaria; Sulfadoxine pyrimethamine

Indexed keywords

ARTEMETHER; FANSIDAR;

ADOLESCENT; ARTICLE; BLOOD CULTURE; BLOOD SMEAR; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG RESISTANCE; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; MALARIA; NONHUMAN; PARASITEMIA; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADOLESCENT; ANIMALS; ANTIMALARIALS; ARTEMISININS; CHILD; CHILD, PRESCHOOL; DRUG COMBINATIONS; FEMALE; HUMANS; INFANT; MALARIA, FALCIPARUM; PLASMODIUM FALCIPARUM; PYRIMETHAMINE; REGRESSION ANALYSIS; SESQUITERPENES; SULFADOXINE; TIME FACTORS; TREATMENT OUTCOME;

EID: 0031862264     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050449     Document Type: Article

References (19)

1. Asawamahasakda W, Ittarat I, Pu Y-M, Ziffer H, Meshnick SR (1994) Reactions of antimalarial endoperoxides with specific parasite proteins. Antimicrob Agents Chemother 38: 1854-1858
2. Geary TG, Divo AA, Jensen JB (1989) Stage specific actions of antimalaria drugs on Plasmodium falciparum in culture. Am J Trop Med Hyg 40: 240-244
3. 3H) isoleucine by Plasmodium falciparum in vitro. Biochem Pharmacol 32: 2463-2466
4. 3H) dihydroartemisinin by erythrocytes infected with Plasmodium falciparum in vitro. Trans R Soc Trop Med Hyg 78: 265-270
5. Hien TT, White NJ (1993) Quinghaosu. Lancet 341: 603-608
6. Jiang JB, Li GQ, Jing R (1982a) Synchronous and independent development of two broods of Plasmodium falciparum in Macaca multata. In: Malaria and other protozoal infections. Proceedings of a Seminar Organized by the Chinese Society of Protozoologists and Zhongson (Sun Yat Sen) University. Guangzhou, China, pp 1-6
7. Jiang JB, Li GQ, Guo XB, Kong YC, Arnold K (1982b) Antimalarial activity of mefloquine and quinghaosu. Lancet ii: 285-288
8. Li GQ, Guo XB, Fu LC, Jian HX, Wang XH (1994) Clinical trials of artemisinin and its derivatives in the treatment of malaria in China. Trans R Soc Trop Med Hyg 88 [Supplement]: S5-6
9. Oduola AMJ, Sowunmi A, Milhons WK, Kyle DE, Martin SK, Walker O, Salako LA (1992) Innate resistance to new antimalarial drugs in Plasmodium falciparum from Nigeria. Trans R Soc Trop Med Hyg 86: 123-127
10. Salako LA, Walker O, Sowunmi A, Omokhodion SA, Adio R, Oduola AMJ (1994) Artemether in moderately severe and cerebral malaria in Nigerian children. Trans R Soc Trop Med Hyg 88 [suppl.]: S13-15
11. Silamut K, White NJ (1993) Relation of the stage of parasite development in the peripheral blood to prognosis in severe falciparum malaria. Trans R Soc Trop Med Hyg 87: 436-443
12. Sowunmi A, Oduola AMJ, Salako LA (1995) Artemether treatment of sulfadoxine pyrimethamine resistant malaria in children. Trans R Soc Trop Med Hyg 89: 435-436
13. Sowunmi A, Salako LA (1992) Evaluation of the relative efficacy of various antimalarial drugs in Nigerian children of five years of age suffering from acute uncomplicated falciparum malaria. Ann Trop Med Parasitol. 86: 1-8
14. Trager W, Jensen JB (1976) Human malaria parasites in continuous culture. Science 193: 673-675
15. Watkins WM, Woodrow C, Marsh K (1993) Falciparum malaria: differential effects of antimalaria drugs on ex vivo parasite viability during the critical early phase of therapy. Am J Trop Med Hyg 49: 106-122
16. White NJ, Walter D, Crawley J, Masten F, Chapman D, Brewster D, Greenwood BM (1992) Comparison of artemether and chloroquine for severe malaria in Gambian children.
17. White NJ, Ho M (1992) Pathophysiology of malaria. Adv Parasitol 33:84-175
18. White NJ, Krishna S (1989) Treatment of malaria: some consideration and limitations of the current methods of assessment. Trans R Soc Trop Med Hyg 83: 767-777
19. WHO (1973) Chemotherapy of malaria and resistance to antimalarials. World Health Organization technical report series no. 529